Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Zheng, Yihu ^a   Yu, Kang ^a   Du, Jimei ^a   Jiang, Lei ^a   Zhang, Shenghui ^a   Han, Yixiang ^a   Yu, Panpan ^a   Tan, Yingxia ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD20 ANTIBODY; CD20 ANTIGEN; CD20 ANTIGEN CD28 ANTIGEN CD3 ANTIGEN ZETA ANTIBODY; CD20 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY ANTIBODY; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; PLASMID DNA; PROTEIN BCL 2; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; CASP3 PROTEIN, HUMAN; CD28 ANTIGEN; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; FAS PROTEIN, HUMAN; HYBRID PROTEIN; IL2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIGEN BINDING; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL THERAPY; CONTROLLED STUDY; CYTOLYSIS; DNA VECTOR; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; CELL SHAPE; COCULTURE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD95; CASPASE 3; CELL LINE, TUMOR; CELL SHAPE; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOMA, NON-HODGKIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 77956479639     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-121     Document Type: Article

References (17)

1. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. M Prichard T Harris ME Williams JJ Densmore, Expert Opin Pharmacother 2009 10 6 983 995 10.1517/14656560902895715 19364248
2. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Z Eshhar T Waks G Gross DG Schindler, Proc Natl Acad Sci USA 1993 90 2 720 724 10.1073/pnas.90.2.720 8421711
3. Treatment of lymphoma with adoptively transferred T cells. BG Till OW Press, Expert Opin Biol Ther 2009 9 11 1407 1425 10.1517/14712590903260785 19723016
4. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. AT Stopeck A Gessner TP Miller EM Hersh CS Johnson H Cui Y Frutiger TM Grogan, Clin Cancer Res 2000 6 10 3904 3909 11051236
5. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. A Krause HF Guo JB Latouche C Tan NK Cheung M Sadelain, J Exp Med 1998 188 4 619 626 10.1084/jem.188.4.619 9705944
6. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. K Yu Y Hu Y Tan Z Shen S Jiang H Qian B Liang D Shan, Leuk Lymphoma 2008 49 7 1368 1373 10.1080/10428190802064958 18452062
7. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. T Van Meerten A Hagenbeek, Neth J Med 2009 67 7 251 259 19687518
8. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. MR Smith, Oncogene 2003 22 47 7359 7368 10.1038/sj.onc.1206939 14576843
9. Stromal gene signatures in large-B-cell lymphomas. G Lenz G Wright SS Dave W Xiao J Powell H Zhao W Xu B Tan N Goldschmidt J Iqbal,, et al. N Engl J Med 2008 359 22 2313 2323 10.1056/NEJMoa0802885 19038878
10. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). N Mounier J Briere C Gisselbrecht JF Emile P Lederlin C Sebban F Berger A Bosly P Morel H Tilly,, et al. Blood 2003 101 11 4279 4284 10.1182/blood-2002-11-3442 12576316
11. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. LJ Cooper L Ausubel M Gutierrez S Stephan R Shakeley S Olivares LM Serrano L Burton MC Jensen SJ Forman DL DiGiusto, Cytotherapy 2006 8 105 117 10.1080/14653240600620176 16698684
12. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Rosenblatt Z Wu B Vasir C Zarwan R Stone H Mills T Friedman PA Konstantinopoulos D Spentzos M Ghebremichael,, et al. J Immunother 2010 33 155 166 10.1097/CJI.0b013e3181bed253 20145548
13. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. L Wall F Burke C Barton J Smyth F Balkwill, Clin Cancer Res 2003 9 7 2487 2496 12855622
14. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. K Handa R Suzuki H Matsui Y Shimizu K Kumagai, J Immunol 1983 130 2 988 992 6294182 (Pubitemid 13186340)
15. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. E Maraskovsky WF Chen K Shortman, J Immunol 1989 143 4 1210 1214 2501391
16. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. T Oltersdorf SW Elmore AR Shoemaker RC Armstrong DJ Augeri BA Belli M Bruncko TL Deckwerth J Dinges PJ Hajduk,, et al. Nature 2005 435 7042 677 681 10.1038/nature03579 15902208
17. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. JC Byrd S Kitada IW Flinn JL Aron M Pearson D Lucas JC Reed, Blood 2002 99 3 1038 1043 10.1182/blood.V99.3.1038 11807010